Clinical Trials Browser

Interventional × dostarlimab × Plasma cell × Clear all

NCT04126200 2025-11-06

DREAMM5

Phase 2 Active not recruiting

Multiple Myeloma

NCT06655818 2025-03-03

Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Dostarlimab (GSK4057190) in Participants With RRMM

Phase 1/2 Terminated

4 enrolled 16 charts

Multiple Myeloma